Showing results (131-140 of 371) with videos related to

Sort By:
Pageof 38
International Clinical Psychopharmacology|October 3, 2006
Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trialsMichela Nosè, Andrea Cipriani, Bruno Biancosino, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 24, 2007
Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practiceAndrea Cipriani, John R Geddes, Toshi A Furukawa, et al.
Epidemiologia E Psichiatria Sociale|April 6, 2006
[Antidepressant and antipsychotic drug prescribing in Lombardy]Mauro Percudani, Corrado Barbui, Ida Fortino, et al.
Schizophrenia Bulletin|April 26, 2008
Does the addition of a second antipsychotic drug improve clozapine treatment?Corrado Barbui, Alessandra Signoretti, Serena Mulè, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 10, 2005
International dosage differences in fluoxetine clinical trialsScott Patten, Andrea Cipriani, Paolo Brambilla, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 24, 2007
Long-term treatment of depression with antidepressants: a systematic narrative reviewToshi A Furukawa, Andrea Cipriani, Corrado Barbui, et al.
European Journal of Clinical Pharmacology|January 9, 2017
Can systematic reviews contribute to regulatory decisions?Corrado Barbui, Antonio Addis, Laura Amato, et al.
JAMA Network Open|August 20, 2024
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and SuicidalityGeorgios Schoretsanitis, Stefan Weiler, Corrado Barbui, et al.
The Lancet Regional Health. Europe|April 20, 2026
Implementation and effectiveness of the WHO Self-Help Plus (SH+) intervention in the Gaza Strip: a prospective hybrid type 1 non-randomised studyYasser Abujamei, Federico Tedeschi, Marianna Purgato, et al.
Psychotherapy and Psychosomatics|August 28, 2020
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting SystemChiara Gastaldon, Emanuel Raschi, John M Kane, et al.
Pageof 38